Dr. Mei Tang
Claim this profileGreater Baltimore Medical Center
Expert in Parotid Gland Cancer
Studies Lung Cancer
17 reported clinical trials
42 drugs studied
About Mei Tang
Education:
- Obtained MD from the University of Maryland School of Medicine in 2015.
- Completed Residency in Internal Medicine at Greater Baltimore Medical Center, serving as Chief Resident (2018-2019).
- Pursued a Fellowship in Hematology and Oncology at Johns Hopkins University School of Medicine (2019-2022).
Experience:
- Currently an attending physician in Hematology and Oncology at Greater Baltimore Medical Center.
Area of expertise
1Parotid Gland Cancer
Global LeaderStage IV
Stage III
Stage II
2Lung Cancer
Stage IV
Stage III
Stage II
Affiliated Hospitals
Clinical Trials Mei Tang is currently running
Crizotinib
for Non-Small Cell Lung Cancer
This randomized phase III trial studies how well crizotinib works in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.
Recruiting2 awards Phase 328 criteria
Nivolumab + Ipilimumab + Sargramostim
for Advanced Melanoma
This phase II/III trial studies the side effects of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery (unresectable) and that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as ipilimumab and nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.
Recruiting1 award Phase 2 & 323 criteria
More about Mei Tang
Clinical Trial Related8 years of experience running clinical trials · Led 17 trials as a Principal Investigator · 6 Active Clinical TrialsTreatments Mei Tang has experience with
- Cisplatin
- Nivolumab
- Intensity-Modulated Radiation Therapy
- Ipilimumab
- Pembrolizumab
- Carboplatin
Breakdown of trials Mei Tang has run
Parotid Gland Cancer
Lung Cancer
Non-Small Cell Lung Cancer
Skin Cancer
Cancer
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
What does Mei Tang specialize in?
Is Mei Tang currently recruiting for clinical trials?
Are there any treatments that Mei Tang has studied deeply?
What is the best way to schedule an appointment with Mei Tang?
What is the office address of Mei Tang?
Is there any support for travel costs?
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.